The Scientific Advisory Board is responsible for advising Oncimmune on its scientific strategy. It consists of some of the world’s leading experts in cancer prevention and diagnosis, and in the science of immunoassays. Members of the Scientific Advisory Board also take on responsibility for overseeing and guiding key research and development projects at the request of Oncimmune’s Science Committee.
The Scientific Advisory Board of Oncimmune is:
Professor Gabriel N. Hortobagyi, MD, FACP is currently the Nellie B. Connally Chair in Breast Cancer Research, Director of the Breast Cancer Research program of UTMD Anderson Cancer Center and Chairman of the Department of Breast Medical Oncology. Dr Hortobagyi has dedicated all of his clinical and research efforts to breast cancer since the completion of his fellowship training at UTMD Anderson Hospital, Houston, Texas in 1976.
Professor Peter Boyle, BSc PhD DSc (Med) DSc FRSE FFPH FRCPS (Glas) FRCP (Edin) FMedSci is President of the International Prevention Research Institute, Lyon, France and was previously Director of the International Agency for Research on Cancer (IARC/WHO) from 2004 to 2008 in Lyon, France. Professor Boyle is also currently Honorary Professor of Cancer Prevention and Control at Oxford University and Visiting Professor at Glasgow University.
Professor David Kerr CBE, MA MD DSc FRCP (Glas & Lon) FRCGP (Hon) FMedSci is Rhodes Professor of Clinical Pharmacology and Cancer Therapeutics at the Department of Clinical Pharmacology, Fellow of Corpus Christi College, University of Oxford. Currently Professor Kerr is the President of European Society of Medical Oncology (ESMO) and chairs the ESMO Board of Directors and Executive Committee. He also serves on the Board of Directors of European Cancer Organisation (ECCO) and is Committee Member of Nominating Committee of ESMO. Treatment and research in colorectal cancer and gene therapy are Professor Kerr’s main areas of interest in research. He is Board Certified by the General Medical Council in the UK and serves as a member of the United Kingdom National Cancer Task Force.
Professor Herb Fritsche, PhD, MD received his BS degree in Chemistry from the University of Houston in 1963, a Masters degree (1965) and a PhD (1968) in Chemistry from Texas A & M University. He has sat on a number of committees of professional societies, been involved with several Scientific Advisory Boards and has numerous honours and awards. He has been Chief Science Officer of Health Discovery Corp. since September 2010. He has been appointed Senior Vice President and member of Board of Directors since July 2011. Prior to joining Health Discovery Corp. Dr. Fritsche was Professor of laboratory Medicine and Chief Chemistry Section at The University of Texas, MD Anderson Cancer Center in Houston, Texas. During his 41 years at MD Anderson Cancer Center, Dr. Fritsche focused his research activities on the development and validation of cancer diagnostics. His research activities included some of the earliest work in tumour markers, more recently, tests for circulating DNA, urine mRNA for bladder cancer detection and circulating tumour cell assays for establishing prognosis of patients with metastatic cancers.
Dr George H. Parsons, PhD is the Managing Director and founder of Parsons Group LLC, an in vitro diagnostics consulting Company, serving clients in the US and Europe. He received his BA in Chemistry (magna cum laude) from Boston University and his MA and PhD in Physical Organic Chemistry from Brandeis University. After teaching for 2 years at Boston University, he entered the business world as a development chemist for Clinical Assays, Inc in Cambridge, MA. Dr Parsons is the inventor or co–inventor on 11 allowed US patents, has authored many peer reviewed articles and book chapters on immunoassay. In the 35 year he has been in the industry, Dr Parsons and his groups have introduced more than 85 assays to the market. He has also been the Chair of the Oak Ridge meeting sponsored by AACC and has been active in local AACC Section activities as Program Chair, Chair and currently Membership Chair.
Dr Zhiping Li, is the Associate Professor of Medicine and Director of Hepatology at Johns Hopkins University School of Medicine. Dr Li had his initial medical education at Shanghai Jiaotong University (formally Shanghai Second Medical University) in China. After finishing his internal medicine resident training in Case Western Reserve University, Dr Li joined Johns Hopkins Gastroenterology and Hepatology in 2000 as a clinic fellow. After his GI fellowship, Dr Li became a faculty member at Johns Hopkins in 2004. He is the Director of Hepatology and is actively engaging in both clinical and basic research, teaching medical students, residents and fellows, and maintaining a busy clinic practice. He is also the Assistant Director of International Medical Education and responsible for all international medical education activities associated with the Johns Hopkins University School of Medicine. Dr Li is specialised in all aspects of liver and biliary diseases, as well as liver transplant. He is board-certified in gastroenterology. He is among the first group of physicians in the US to be board certified in Transplant Hepatology.
Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).
These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.
None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.
By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.